160 related articles for article (PubMed ID: 10760430)
1. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
Shulman LN; Buswell L; Riese N; Doherty N; Loeffler JS; von Roemeling RW; Coleman CN
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):349-53. PubMed ID: 10760430
[TBL] [Abstract][Full Text] [Related]
2. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation.
Doherty N; Hancock SL; Kaye S; Coleman CN; Shulman L; Marquez C; Mariscal C; Rampling R; Senan S; Roemeling RV
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):379-82. PubMed ID: 8195037
[TBL] [Abstract][Full Text] [Related]
3. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.
Del Rowe J; Scott C; Werner-Wasik M; Bahary JP; Curran WJ; Urtasun RC; Fisher B
J Clin Oncol; 2000 Mar; 18(6):1254-9. PubMed ID: 10715295
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of i.v. administered tirapazamine plus cyclophosphamide.
Hoff PM; Saad ED; Ravandi-Kashani F; Czerny E; Pazdur R
Anticancer Drugs; 2001 Jul; 12(6):499-503. PubMed ID: 11459995
[TBL] [Abstract][Full Text] [Related]
7. Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075).
Spiegel JF; Spear MA; Brown JM
Radiother Oncol; 1993 Jan; 26(1):79-81. PubMed ID: 8438092
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.
Senan S; Rampling R; Graham MA; Wilson P; Robin H; Eckardt N; Lawson N; McDonald A; von Roemeling R; Workman P; Kaye SB
Clin Cancer Res; 1997 Jan; 3(1):31-8. PubMed ID: 9815534
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.
Johnson CA; Kilpatrick D; von Roemeling R; Langer C; Graham MA; Greenslade D; Kennedy G; Keenan E; O'Dwyer PJ
J Clin Oncol; 1997 Feb; 15(2):773-80. PubMed ID: 9053504
[TBL] [Abstract][Full Text] [Related]
10. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Lara PN; Frankel P; Mack PC; Gumerlock PH; Galvin I; Martel CL; Longmate J; Doroshow JH; Lenz HJ; Lau DH; Gandara DR
Clin Cancer Res; 2003 Oct; 9(12):4356-62. PubMed ID: 14555506
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer.
Craighead PS; Pearcey R; Stuart G
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):791-5. PubMed ID: 11020576
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Pugh TJ; Chen C; Rabinovitch R; Eckhardt SG; Rusthoven KE; Swing R; Raben D
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):521-6. PubMed ID: 20133082
[TBL] [Abstract][Full Text] [Related]
14. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device.
Yapp DT; Lloyd DK; Zhu J; Lehnert S
Radiother Oncol; 1999 Oct; 53(1):77-84. PubMed ID: 10624857
[TBL] [Abstract][Full Text] [Related]
16. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study.
Lee DJ; Trotti A; Spencer S; Rostock R; Fisher C; von Roemeling R; Harvey E; Groves E
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):811-5. PubMed ID: 9845102
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.
Aquino VM; Weitman SD; Winick NJ; Blaney S; Furman WL; Kepner JL; Bonate P; Krailo M; Qu W; Bernstein M
J Clin Oncol; 2004 Apr; 22(8):1413-9. PubMed ID: 15084615
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
Kavanagh BD; Khandelwal SR; Schmidt-Ullrich RK; Roberts JD; Shaw EG; Pearlman AD; Venitz J; Dusenbery KE; Abraham DJ; Gerber MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1133-9. PubMed ID: 11240256
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
Marcus KJ; Dutton SC; Barnes P; Coleman CN; Pomeroy SL; Goumnerova L; Billett AL; Kieran M; Tarbell NJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1182-5. PubMed ID: 12654425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]